According to ChainCatcher, FinChip and AgentOn announced a merger agreement today to form a unified company branded as Finch, simultaneously completing a pre-A funding round at a $50 million valuation. Water Drop Capital, Peer VC, and other institutions participated in the round. Finch had

According to Japan Exchange Group, Global X Japan listed the Global X Korea Semiconductor Top 10 ETF on the Tokyo Stock Exchange today, September 9. The ETF tracks the FnGuide Semiconductor Top 10 index in yen-denominated form, allocating 25% each to Samsung Electronics and SK Hynix for half of

According to SpaceX's SEC Form 424B4 prospectus filed on June 12, 2026, up to 319.0 million Class A shares unlocked today (day 90 of the 180-day lock-up period), representing 7% of locked shares and excluding Rule 144 affiliate holdings. A separate 59.1 million affiliate block becomes tradable

According to ChainCatcher, on September 8, OpenAI announced its multi-agent system has successfully proved that three-dimensional incompressible Navier-Stokes equations can form finite-time singularities, solving a century-old mathematical problem. The proof, derived by a model stronger than GPT-6 A

According to PANews, on September 9, OpenAI announced that its internal system provided a solution to the Navier-Stokes existence and smoothness problem: under smooth external forces, an initially static and smooth three-dimensional incompressible fluid can form singularities in finite time while

Meta Platforms released a new AI agent called Muse on September 8, designed to automate personal tasks for U.S. users. Muse can handle online shopping, movie ticket purchases, schedule bookings, and form submissions. The company plans to eventually

According to its SEC Form 8-K filing released Tuesday, Strive (ASST) acquired 1,375 bitcoin for approximately $109 million between Aug. 31 and Sept. 4 at an average price of $79,281 per BTC. The purchase brings Strive's total bitcoin holdings to 24,531 BTC.
Strive CEO Matt Cole noted

According to Novartis, the company's jointly developed drug pelacarsen with Ionis Pharmaceuticals recently failed to significantly improve cardiovascular outcomes in a late-stage trial, despite successfully reducing Lp(a), a particularly harmful form of cholesterol.
This marks the first major